Experience of laboratorians participation in the treatment of complex pulmonary multidrug resistant bacteria infection

doi:10.3877/cma.j.issn.1674-1358.2019.05.003

Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition) ›› 2019, Vol. 13 ›› Issue (05): 362-365. doi: 10.3877/cma.j.issn.1674-1358.2019.05.003

Special Issue: ；

• Articles of Bacterial Drugresistance • Previous Articles Next Articles

Experience of laboratorians participation in the treatment of complex pulmonary multidrug resistant bacteria infection

Jiahong Wang¹, Panfei Hou², Yan Pan², Lijing Zhu²^,^†()

^1. Department of Clinical Laboratory, Yixing No. 2 People’s Hospital, Yixing 214221, China
^2. Department of Clinical Laboratory, Lianshui People’s Hospital, Affiliated Kangda College of Nanjing Medical University, Lianshui 223400, China

Received:2019-02-22 Online:2019-10-15 Published:2019-10-15
Contact: Lijing Zhu
About author:
Corresponding author: Zhu Lijing, Email: zhulijing830710@126.com

Abstract

Abstract:

Objective

To discuss the role of laboratorians in the treatment of complex multidrug-resistant bacteria.

Methods

One laboratorians participated in the treatment of one patient admitted in Yixing No. 2 People’s Hospital on May 20th 2017 who was infected by Klebsiella pneumoniae carrying Extended-spectrum β-lactamases (ESBLs), Mycoplasma pneumonia and extensively drug resistant Acinetobacter Bauman. Treatment was provided to clinicians and the clinical efficacy was evaluated.

Results

According to the drug sensitivity results and drug resistance mechanism analysis, the laboratorians suggested that high dose imipenem (intravenous drip 1.0 g every 6 hours) should be used and the drip time should be prolonged to 2-3 hours. The patient had no fever, cough and asthma after treatment. Blood routine and other indicators returned to normal, and bacterial culture was negative.

Conclusions

Laboratorians participating in clinical anti-infection treatment, and providing reasonable advice for clinicians could improve clinical cure rate of complex multidrug-resistant bacteria infection.

Key words: Extended-Spectrum-β-lactamases, Extensively drug resistant Acinetobacter baumannii, Anti-infective therapy

Jiahong Wang, Panfei Hou, Yan Pan, Lijing Zhu. Experience of laboratorians participation in the treatment of complex pulmonary multidrug resistant bacteria infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(05): 362-365.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.05.003

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I05/362

Figures/Tables 1

References 20

[1]	黄勋,邓子德,倪语星, 等. 多重耐药菌医院感染预防与控制中国专家共识[J]. 中国感染控制杂志,2015,14(1):1-9.
[2]	Seruga Music M,Hrenovic J,Goic-Barisic I, et al. Emission of extensively- drug-resistant Acinetobacter baumannii from hospital settings to the natural environment[J]. J Hosp infect,2017,96(4):323-327.
[3]	张驰,凌保东. 多重耐药和广泛耐药鲍曼不动杆菌感染治疗的药物选择[J]. 微生物与感染,2018,13(2):90-96.
[4]	Kim YJ,Kim SI,Lee YD, et al. Carbapenem-resistant Acinetobacter baumannii bacteremia in liver transplant recipients[J]. Transplant Proc,2018,50(4):1132-1135.
[5]	刘成,孙宁,侯盼飞. 2015年乳山市人民医院细菌耐药性监测[J/CD]. 中华实验和临床感染病杂志(电子版),2017,11(4):364-367.
[6]	张鹏,周燕斌,黄炎明, 等. 多重耐药鲍曼不动杆菌医院获得性肺炎的危险因素及预后分析[J]. 中国感染与化疗杂志,2015,15(6):527-532.
[7]	杨欣刚,安海龙,马修尧, 等. 重型颅脑损伤患者气管切开术后肺部感染特点与危险因素分析[J]. 中华医院感染学杂志,2016,26(2):323-325.
[8]	谢金兰,秦颖,姚惠, 等. 2013至2015年某院大肠埃希菌的临床分布及耐药趋势[J/CD]. 中华实验和临床感染病杂志(电子版),2017,11(3):232-238.
[9]	黄健云,芮勇宇,莫和国, 等. 呼吸系统鲍曼不动杆菌的感染现况及耐药性分析[J]. 现代预防医学,2015,41(11):143-145.
[10]	Matsui M,Suzuki M,Suzuki M, et al. Distribution and molecular characterization of Acinetobacter baumannii international clone Ⅱ lineage in Japan[J]. Antimicrob Agents Chemother,2018,62(2):e02190-17.
[11]	Brown ED,Wright GD. Antibacterial drug discovery in the resistance era[J]. Nature,2016,529(7586):336-343.
[12]	潘艳,祝丽晶,陈小颖, 等. 近三年鲍曼不动杆菌耐药性变迁及外排泵基因研究[J]. 中国微生态学杂志,2019,31(1):62-65.
[13]	Rodriguez CH,Balderrama Yarhui N,Nastro M, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in South America[J]. J Med Microbiol,2016,65(10):1088-1091.
[14]	胡付品,郭燕,朱德妹, 等. 2017年CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2018,18(3):241-251.
[15]	Ramette A,Kronenberg A. Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland[J]. BMC Infect Dis,2018,18(1):159-165.
[16]	Upadhyay S,Khyriem AB,Bhattacharya P, et al. High-level aminoglycoside resistance in Acinetobacter baumannii recovered from Intensive Care Unit patients in Northeastern India[J]. Indian J Med Microbiol,2018,36(1):43-48.
[17]	中国医药教育协会感染疾病专业委员会, 《中华结核和呼吸杂志》编辑委员会,中国药学会药物临床评价研究专业委员会. 抗菌药物超说明书用法专家共识[J]. 中华结核和呼吸杂志,2015,38(6):410-444.
[18]	陈佰义,何礼贤,胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志,2012,92(2):76-85.
[19]	国家卫生和计划生育委员会. 抗菌药物临床应用指导原则(2015)版[S]. 国卫办医发[2015]43号．
[20]	祝丽晶,高玉强,宋宁，等. 检验师参与1例泛耐药鲍曼不动杆菌治疗的临床实践[J]. 国际检验医学杂志,2017,38(21):3066-3067.

抗菌药物	MIC（mg/L）	敏感度
环丙沙星	≥ 4	耐药
左氧氟沙星	≥ 8	耐药
复方磺胺/甲氧苄啶	≥ 8/128	耐药
氨苄西林/舒巴坦	≥ 64/32	耐药
头孢哌酮/舒巴坦	≥ 64/32	耐药
哌拉西林/他唑巴坦	≥ 128/4	耐药
替卡西林/克拉维酸	≥ 128/2	耐药
阿米卡星	≥ 32	耐药
庆大霉素	≥ 16	耐药
亚胺培南	8	耐药
美罗培南	16	耐药
头孢吡肟	≥ 32	耐药
头孢他啶	≥ 32	耐药
多黏菌素B	≤ 2	敏感

抗菌药物	MIC（mg/L）	敏感度
环丙沙星	≥ 4	耐药
左氧氟沙星	≥ 8	耐药
复方磺胺/甲氧苄啶	≥ 8/128	耐药
氨苄西林/舒巴坦	≥ 64/32	耐药
头孢哌酮/舒巴坦	≥ 64/32	耐药
哌拉西林/他唑巴坦	≥ 128/4	耐药
替卡西林/克拉维酸	≥ 128/2	耐药
阿米卡星	≥ 32	耐药
庆大霉素	≥ 16	耐药
亚胺培南	8	耐药
美罗培南	16	耐药
头孢吡肟	≥ 32	耐药
头孢他啶	≥ 32	耐药
多黏菌素B	≤ 2	敏感

Please choose a citation manager

Content to export

Experience of laboratorians participation in the treatment of complex pulmonary multidrug resistant bacteria infection

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 20

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Experience of laboratorians participation in the treatment of complex pulmonary multidrug resistant bacteria infection

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 20

Related Articles 0

Recommended Articles

Metrics

Comments